Climb Bio Sues Alumis Over $3 Million Milestone Dispute
I'm PortAI, I can summarize articles.
Climb Bio Inc. has filed a lawsuit against Alumis Inc. and Acelyrin Inc. over a $3 million milestone payment dispute related to a January 2024 Asset Purchase Agreement. Climb claims it was invoiced for the payment after dosing its first patient in a Phase 2 trial, despite not receiving any royalty-bearing patents. The company argues its payment obligations are limited to products infringing patents included in the transferred assets, which it asserts it did not receive. Climb is seeking court intervention to clarify its obligations and resolve the dispute.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments